Tymora Analytical Operations specializes in non-invasive biomarker discovery, focusing on the analysis of extracellular vesicles (EVs), particularly exosomes, to enhance the understanding and diagnosis of diseases such as cancer and Alzheimer’s. Their innovative technology, known as EVtrap (Extracellular Vesicles Total Recovery and Purification), allows for the efficient recovery and purification of EV proteins and phosphoproteins from minimal biological fluid samples, such as plasma and urine. This method significantly improves the identification of unique proteins, enabling researchers to detect over 1,000 distinct proteins from just 0.01 mL of plasma or 0.2 mL of urine, which is a notable advancement compared to previous techniques.

In addition to EVtrap, Tymora Analytical offers a range of products and services, including the pIMAGO technology for phosphoprotein detection and the PolyMAC protocol for phosphopeptide enrichment. These technologies facilitate the analysis of disease-relevant signaling marker proteins, providing researchers with real-time insights into disease progression without the need for invasive tissue biopsies. By partnering with various stakeholders, including pharmaceutical and biotechnology companies, Tymora Analytical aims to support innovative research and the development of companion diagnostics, ultimately contributing to advancements in life sciences and improved patient outcomes.

United States

Tymora Analytical Operations provides new research services, products, and reagents to the life science R&D organizations. Tymora has developed nanoscale platform technologies – with PolyMAC and pIMAGO as the lead products – for unmet needs in analysis of protein phosphorylation that relates to the onset of numerous diseases, most notably cancer

Tymora Analytical Operations

Company Details